chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal distension, Fluid retention, Lymphadenopathy, Peripheral swelling, Swelling
Clinical narrative: swelling all over face, neck, lymphnodes, abdomen, and hands.; swelling all over face, neck, lymphnodes, abdomen, and hands.; swelling all over face, neck, lymphnodes, abdomen, and hands.; swelling all over face, neck, lymphnodes, abdomen, and hands.; swelling all over face, neck, lymphnodes, abdomen, and hands.; Water retention still in hands, neck abdomen breasts, and lymphnodes; This is a spontaneous report from a contactable consumer (patient reported for herself). A 62-years-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, solution for injection, Lot Number: 6955, expiry date not reported) via an unspecified route of administration, administered in left arm on 25Mar2021 (at the age of 62 years old as reported) as dose 2, single for covid-19 immunization. Medical history included known allergies to insects, bees and penicillin products. The patient was not pregnant at the time of the vaccination and report. The patient had no concomitant medications. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient had not received other medications within 2 weeks of vaccination. The patient previously received Covid-19 vaccine (bnt162b2) for covid-19 immunisation on 04Mar2021 at 2:00pm at the age of 62 years old (lot number EN6204) administered in the right arm. The patient previously took amoxicillin and experienced allergy. On 27Mar2021 12:00, two days after shot, the patient had swelling all over face, neck, lymphnodes, abdomen, and hands. Doctor said to take Benadryl however patient had continued swelling and went back to doctor and was given 5 day methylprednisone. Patient was then still swelling and got steroid shot. One day fine, then back to swelling in all areas. On Saturday, patient had 3 day steroid shot.  Water retention still in hands, neck abdomen, breasts, and lymphnodes (since 27Mar2021 12:00).  Patient was taking claritin/ benydryl to help with symptoms and worst in the morning when awaken. Patient was sleeping sitting up. The events resulted in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. The events were reported as serious medically significant. Therapeutic measures were taken in response to the events which included steroid shots, and antihistamines, along with prednisone. Since the vaccination, the patient has not been tested for COVID-19.  The patient had not recovered from the events reported.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Swelling face
Clinical narrative: swelling all over face, neck, lymphnodes, abdomen, and hands.; swelling all over face, neck, lymphnodes, abdomen, and hands.; swelling all over face, neck, lymphnodes, abdomen, and hands.; swelling all over face, neck, lymphnodes, abdomen, and hands.; swelling all over face, neck, lymphnodes, abdomen, and hands.; Water retention still in hands, neck abdomen breasts, and lymphnodes; This is a spontaneous report from a contactable consumer (patient reported for herself). A 62-years-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, solution for injection, Lot Number: 6955, expiry date not reported) via an unspecified route of administration, administered in left arm on 25Mar2021 (at the age of 62 years old as reported) as dose 2, single for covid-19 immunization. Medical history included known allergies to insects, bees and penicillin products. The patient was not pregnant at the time of the vaccination and report. The patient had no concomitant medications. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient had not received other medications within 2 weeks of vaccination. The patient previously received Covid-19 vaccine (bnt162b2) for covid-19 immunisation on 04Mar2021 at 2:00pm at the age of 62 years old (lot number EN6204) administered in the right arm. The patient previously took amoxicillin and experienced allergy. On 27Mar2021 12:00, two days after shot, the patient had swelling all over face, neck, lymphnodes, abdomen, and hands. Doctor said to take Benadryl however patient had continued swelling and went back to doctor and was given 5 day methylprednisone. Patient was then still swelling and got steroid shot. One day fine, then back to swelling in all areas. On Saturday, patient had 3 day steroid shot.  Water retention still in hands, neck abdomen, breasts, and lymphnodes (since 27Mar2021 12:00).  Patient was taking claritin/ benydryl to help with symptoms and worst in the morning when awaken. Patient was sleeping sitting up. The events resulted in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. The events were reported as serious medically significant. Therapeutic measures were taken in response to the events which included steroid shots, and antihistamines, along with prednisone. Since the vaccination, the patient has not been tested for COVID-19.  The patient had not recovered from the events reported.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Anosmia, Body temperature, Cough, Headache, Nasal congestion
Clinical narrative: Coughing; Headache; Slight loss of smell; Body aches; slight temp (99.5); congestion; This is a spontaneous report from a contactable consumer, the patient. A 47-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 31Mar2021 at 10:45(at the age of 47-year-old) as a single dose for COVID-19 immunisation. Medical history included hypertension and seasonal allergy. The patient received medications within two weeks of vaccination which are unspecified. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, it was unknown whether the patient had been tested for COVID-19. On 03Apr2021 at 00:00 the patient experienced nasal congestion, Coughing, Headache, Slight loss of smell, Body aches and slight temp (99.5). The patient did not receive any treatment for the events. The events didn't result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event nasal congestion, slight temp (99.5), coughing, headache, slight loss of smell, body aches were not resolved.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Pyrexia
Clinical narrative: Coughing; Headache; Slight loss of smell; Body aches; slight temp (99.5); congestion; This is a spontaneous report from a contactable consumer, the patient. A 47-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 31Mar2021 at 10:45(at the age of 47-year-old) as a single dose for COVID-19 immunisation. Medical history included hypertension and seasonal allergy. The patient received medications within two weeks of vaccination which are unspecified. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, it was unknown whether the patient had been tested for COVID-19. On 03Apr2021 at 00:00 the patient experienced nasal congestion, Coughing, Headache, Slight loss of smell, Body aches and slight temp (99.5). The patient did not receive any treatment for the events. The events didn't result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event nasal congestion, slight temp (99.5), coughing, headache, slight loss of smell, body aches were not resolved.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Headache
Clinical narrative: Knee pain; Head pain; This is a spontaneous report from a non-contactable consumer, the patient. A 70-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in the left arm on 02Feb2021 (at the age of 70-years-old) as a single dose for COVID-19 immunisation. The patient also received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9266), via an unspecified route of administration in the left arm on 23Feb2021 at 10:15 (at the age of 70-years-old) as a single dose for COVID-19 immunisation. Medical history included unspecified allergies. Concomitant medication included levothyroxine (LEVOTHYROXINE) taken from an unknown date for an unknown indication.  Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On an unspecified date in 2021, the patient experienced knee pain and head pain. The events did not result in a doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. care. The clinical outcome of the events knee pain and head pain was unknown at the time of this report.   No follow-up attempts are possible; information about lot number cannot be obtained.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Dyskinesia, Dysphagia, Feeling hot, Thirst, Throat tightness
Clinical narrative: Heat sensation at base of throat which shot up to both sides of my throat and very hot sensation in face.; Throat tightened; Hard time swallowing.; Jerky moves in my leg muscles; Very thirsty; This is a spontaneous report from a contactable consumer, the patient. A 63-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN, Ndc: 59267-1000-01) via an unspecified route of administration in the arm left on 23Mar2021 at 11:30 (at the age of 63-years-old) as a single dose for COVID-19 immunisation. Medical history included cholesterol, shellfish allergy and penicillin allergy. Concomitant medications included rosuvastatin (MANUFACTURER UNKNOWN) for unknown indication from an unknown date. The patient previously received erythromycin base (MANUFACTURER UNKNOWN) for unknown indication on an unknown date and experienced drug allergy.  Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On an unknown date in Mar2021, the patient had a rolling heat sensation at base of throat which shot up to both sides of the throat and very hot sensation in the face. The patient's throat tightened up and had a hard time swallowing. The patient had jerky moves in leg muscles which where do the right thought, it was as if the patient was going to have a "Charlie horse" in both calves.  Symptoms calmed down by 17:00 that day. The patient was very thirsty and throat still unstable but calmer. The patient did not receive any treatment for the events. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events sensation of heat, jerkiness and swallowing difficulty were recovered on an unknown date in Mar2021, while that of the events throat tightness and thirst were recovering at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Body temperature, Chills, Headache, Hyperhidrosis
Clinical narrative: Sweating; Fever 102.8; Chills; Malaise; Myalgia; Arthralgia; Headache; This is a spontaneous report from a contactable nurse. A 38-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in the left arm on 17Mar2021 at 10:15 (at the age of 38-years-old), as a single dose for COVID-19 immunisation. Medical history included depression, hashimoto's disease, acute kidney injury, catfish allergy, bivalved shellfish allergy and house dust mite allergy. Concomitant medications included bupropion hydrochloride (WELLBUTRIN), olanzapine (ZYPREXA), desvenlafaxine succinate monohydrate (PRISTIQ), thyroid (ARMOUR THYROID) and hydroxyzine (ATARAX); all drugs started on an unknown date for unknown indication. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in the left arm on 24Feb2021 at 10:15 (at the age of 38-years-old), as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the vaccination. On 19Mar2021 at 12:00, the patient experienced fever 102.8 (unit unspecified), chills, sweating, malaise, myalgia, arthralgia and headache. No therapeutic measures were taken as a result of the reported events. The events did not result in doctor or other healthcare professional office or clinic visit, and emergency room or department or urgent care. The patient received an unknown vaccine on 01Apr2021 for unknown indication. The clinical outcome of the events fever 102.8, chills, sweating, malaise, myalgia, arthralgia and headache were recovered on an unknown date in 2021.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Malaise, Myalgia, Pyrexia
Clinical narrative: Sweating; Fever 102.8; Chills; Malaise; Myalgia; Arthralgia; Headache; This is a spontaneous report from a contactable nurse. A 38-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in the left arm on 17Mar2021 at 10:15 (at the age of 38-years-old), as a single dose for COVID-19 immunisation. Medical history included depression, hashimoto's disease, acute kidney injury, catfish allergy, bivalved shellfish allergy and house dust mite allergy. Concomitant medications included bupropion hydrochloride (WELLBUTRIN), olanzapine (ZYPREXA), desvenlafaxine succinate monohydrate (PRISTIQ), thyroid (ARMOUR THYROID) and hydroxyzine (ATARAX); all drugs started on an unknown date for unknown indication. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in the left arm on 24Feb2021 at 10:15 (at the age of 38-years-old), as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the vaccination. On 19Mar2021 at 12:00, the patient experienced fever 102.8 (unit unspecified), chills, sweating, malaise, myalgia, arthralgia and headache. No therapeutic measures were taken as a result of the reported events. The events did not result in doctor or other healthcare professional office or clinic visit, and emergency room or department or urgent care. The patient received an unknown vaccine on 01Apr2021 for unknown indication. The clinical outcome of the events fever 102.8, chills, sweating, malaise, myalgia, arthralgia and headache were recovered on an unknown date in 2021.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: Heart rate, Heart rate increased, Hot flush, Miliaria
Clinical narrative: Immediate hot flash; Prickly heat; Rapid pulse over 110; This is a spontaneous report from a contactable consumer, the patient. A 59-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm right on 02Apr2021 at 13:00 (at the age of 59-year-old) as a single dose for COVID-19 immunisation. Medical history included graves' disease and allergy to antibiotics. Concomitant medications included levothyroxine sodium (SYNTHROID) and clonazepam (MANUFACTURER UNKNOWN). The patient previously took TAGAMET for unknown indication and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 02Apr2021 at 13:00, the patient had experienced immediate hot flash, prickly heat and rapid pulse over 110. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. No therapeutic measures were taken as the result of adverse events. The clinical outcome of the events hot flash, prickly heat and rapid pulse was recovered on an unknown date in 2021.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: severe pain on the bottom base of the thumb; This is a spontaneous report from a contactable consumer, the patient. A 38-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7534) via an unspecified route of administration in the left arm on 01Apr2021 at 15:00 (at the age of 38-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medication were not reported. The patient did not receive any medication within two weeks of vaccination. The patient has no known allergies. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ENG203) via an unspecified route of administration in the left arm on 11Mar2021 at 15:00 (at the age of 38-years-old)  as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 03Apr2021, the patient experienced severe pain on the bottom base of the thumb, it was so painful that the patient cannot close her hand and it hurts when tried to grip anything. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event severe pain on the bottom base of the thumb was not recovered at the time of the report.   No follow-up attempts are needed. No further information is expected.
Age: 60.0
Sex: M
Vaccine: COVID19
Symptoms: Ageusia, Dysgeusia
Clinical narrative: Loss of taste; Tasted very salty; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration in the arm left on 24Mar2021 at 12:30 (at the age of 60-year-old) as a single dose for COVID-19 immunisation. Medical history included high cholesterol and gout (Taking tablets) both are under control. Concomitant medications included allopurinol (MANUFACTURER UNKNOWN) and atorvastatin (MANUFACTURER UNKNOWN); Both from unknown date for unknown indication. The patient had no known allergies to medications, food or other products. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6198) via an unspecified route of administration in the arm left on 03Mar2021 at 18:30 (at the age of 60-year-old) as a single dose for COVID-19 immunisation.  Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 25Mar2021 the patient experienced loss of taste. Everything was bland (no flavor), although some foods taste very salty back to normal the day after. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the event loss of taste and taste very salty was recovered on 26Mar2021.  No follow-up attempts are needed. No further information is expected.
Age: 61.0
Sex: M
Vaccine: COVID19
Symptoms: Insomnia, Tinnitus
Clinical narrative: Developed tinnitus in both ears.; Had trouble sleeping the past few weeks but am sleeping better; This is a spontaneous report from a contactable consumer, the patient. A 61-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) in the arm right on 12Mar2021 at 20:00 (at the age of 61-years-old) and second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) in the arm right on 02Apr2021 at 17:15 (at the age of 61-years-old) as a single dose for COVID-19 immunisation. Medical history included cholesterol and blood pressure high. Concomitant medications included atorvastatin calcium (LIPITOR) 40mg and amlodipine (MANUFACTURER UNKNOWN) 5mg from an unknown date. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. After receiving the first dose on 12March2021, the patient developed tinnitus in both ears late Sunday on 21March2021 into early Monday 22March2021. The patient started to take some over the counter supplements to help. The patient's right ear was normal as of 06April2021 but had slight tinnitus in the left ear. The right tinnitus had resolved several days ago. The patient felt that the left ear was bit better as ringing can dissipate during different times of the day. The patient had trouble sleeping for the past few weeks but was able to sleep better at the time of reporting. The patient was still trying to get the left ear line the right. The patient would clean the ears daily with Q-tips (outer areas) and would always see wax and the weirdest thing was that there was no ear wax. The patient got nothing and no wax at all even if the ears were not cleaned for days which was very, very strange. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of tinnitus, trouble sleeping and included treatment with over-the-counter herbs with ginkgo biloba (MANUFACTURER UNKNOWN) and SYNAPSE XT from 22Mar2021 to unknown date. The clinical outcome of the events tinnitus in ears and difficulty sleeping were recovering at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 29.0
Sex: M
Vaccine: COVID19
Symptoms: Pain
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 29-year-old, male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: ER8737) via an unspecified route in the left arm on 01Apr2021 at 10:30 (at the age of 29-years-old) as a single dose for COVID-19 immunisation. Medical history included lyme disease 15 years ago which resolved with 2 weeks doxycycline. The patient had no known allergies. The patient had no allergies to medications, food, or other products. The patient did not receive any other concomitant medications within  two weeks prior to the COVID-19 vaccine. The past drug history of the patient included doxycycline (MANUFACTURER UNKNOWN) started on an unknown date for lyme disease. Prior to vaccination, it was unknown if the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccination within four weeks prior to the COVID-19 vaccine. On 01Apr2021 at 14:00, the patient had intense pain in left bicep, near where it meets the elbow, felt like his muscle was literally tearing off his bone. He can flex his muscle with no pain. Extending his arm fully causes the intense pain. 6 days after the shot, the patient woke up with the pain spreading to his ribs close to his heart. There was no sign that the pain was decreasing or increasing, just spreading. No therapeutic measures were taken as a result of the reported events. The events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. The clinical outcome of the event intense pain in left bicep was not recovered at the time of this report. No follow-up attempts are needed. No further information is expected.
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: Mass, Pain
Clinical narrative: a hard lump on my chin; When pressed its hurts.; This is a spontaneous report from a contactable consumer, the patient. A 31-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 03Apr2021 at 16:30 (at the age of 31-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 03Apr2021 at 19:00, the patient started to have a hard lump on her chin the same day after she got vaccinated. It had been 2 days and the lump was growing, when pressed it hurts and now the size was around a ping pong ball size. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken for the reported events. The clinical outcome of the events hard lump on the chin and when pressed it hurts were not recovered at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 30.0
Sex: M
Vaccine: COVID19
Symptoms: Fatigue, Nausea, Pain, Pyrexia
Clinical narrative: Body aches; Fever; Fatigue; Nausea; This is a spontaneous report from a contactable consumer, the patient. A 30-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 03Apr2021 at 12:30 (at the age of 30-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications included testosterone enanthate (XYOSTED) for an unknown indication  from an unknown date. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 04Apr2021, the patient experienced fever, body aches, fatigue and nausea. The patient did not receive any treatment for the events. The adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events fever, body aches, fatigue and nausea were not recovered at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 61.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Headache, Malaise, Pain, Pyrexia
Clinical narrative: Fever; Chills; Aches; Injection site pain; Headache; Feeling unwell; This is a spontaneous report from a contactable consumer, the patient. A 61-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0151) via an unspecified route of administration in the left arm on 05Apr2021 at 12:45 (at the age of 61-year-old) as a single dose for COVID-19 immunisation. Medical history included blood pressure high and penicillin allergy. Concomitant medications included rosuvastatin (MANUFACTURER UNKNOWN), hydrochlorothiazide (MANUFACTURER UNKNOWN) and Amlodipine-Benazepril (MANUFACTURER UNKNOWN) on an unknown date for an unknown indication. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6208) via an unspecified route of administration in the left arm on 15Mar2021 at 14:00 (at the age of 61-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 06Apr2021 at 01:00, the patient experienced fever, chills, aches, injection site pain, headache and feeling unwell. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported event. The clinical outcome of the events fever, chills, aches, injection site pain, headache and feeling unwell was not recovered.   No follow-up attempts are needed. No further information is expected.
Age: 61.0
Sex: M
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Fever; Chills; Aches; Injection site pain; Headache; Feeling unwell; This is a spontaneous report from a contactable consumer, the patient. A 61-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0151) via an unspecified route of administration in the left arm on 05Apr2021 at 12:45 (at the age of 61-year-old) as a single dose for COVID-19 immunisation. Medical history included blood pressure high and penicillin allergy. Concomitant medications included rosuvastatin (MANUFACTURER UNKNOWN), hydrochlorothiazide (MANUFACTURER UNKNOWN) and Amlodipine-Benazepril (MANUFACTURER UNKNOWN) on an unknown date for an unknown indication. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6208) via an unspecified route of administration in the left arm on 15Mar2021 at 14:00 (at the age of 61-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 06Apr2021 at 01:00, the patient experienced fever, chills, aches, injection site pain, headache and feeling unwell. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported event. The clinical outcome of the events fever, chills, aches, injection site pain, headache and feeling unwell was not recovered.   No follow-up attempts are needed. No further information is expected.
Age: 63.0
Sex: M
Vaccine: COVID19
Symptoms: Blood test, Epistaxis
Clinical narrative: Nose bleeds; This is a spontaneous report from a contactable consumer, the patient. A 63-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the right arm on 23Mar2021 at 12:00 (at the age of 63-year-old) as a single dose for COVID-19 immunisation. Medical history was reported as none. The patient was not aware of any allergies to medications, food, or other products. Concomitant medications included lisinopril (MANUFACTURER UNKNOWN)  ROVUSTATIN and MULT-VITAMIN from an unknown date, for an unknown indications. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. On 03Apr2021, at 14:30 the patient experienced nose bleeds. It was reported that the patient experienced nose bleeds (heavy) started on 04Apr2021 and have recurred on subsequent days, no particular changes in activities or exercise habits.  On 15Mar2021, the patient underwent blood test and the result was negative. The patient did not receive any treatment for the reported adverse event. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event nose bleeds was unknown at the time of report.   No follow-up attempts are needed. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Abnormal dreams, Headache, Pain, Pain in extremity, Sleep disorder
Clinical narrative: Sore arm; mild headache; strange dreams/disturbed sleep; occasional body aches; strange dreams/disturbed sleep,; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the left arm on 05Apr2021 at 19:00 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Medical history included hypothyroidism, irritable bowel syndrome, GERD and gastritis, allergy to certain soy sauces but not all, and no other soy products. Concomitant medications included pantoprazole sodium sesquihydrate (PROTONIX), levothyroxine sodium (EUTHYROX), loratadine (CLARITIN), ibuprofen (ADVIL), and doxycycline (MANUFACTURER UNKNOWN) from an unknown date for an unspecified indication. The patient previously took Cephalexin (MANAFACTURER UNKNOWN), acetaminophen; hydrocodone (VICODIN), hydrocodone bitartrate; acetaminophen (LORTAB), hydrocodone bitartrate (NORCO) all from an unknown date for an unspecified indication and experienced allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 05Apr2021 at 22:00 the patient experienced sore arm, mild headache, strange dreams/disturbed sleep, occasional body aches. Patient did not receive treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of events pain in arm, headache, sleep disturbance, general body pain, abnormal dreams was resolving at the time of reporting.  No follow-up attempts are needed. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Chills, Headache, Malaise, Pain
Clinical narrative: Very sick with first dose; Fever; Terrible headache; Chills; Intense body aches; Joint pain; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0190) via an unspecified route of administration in the left arm on 03Apr2021 at 16:30 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. The patient had no relevant medical history. The patient did not receive any other medicines within two weeks prior to the COVID-19 vaccine. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 04Apr2021, with first dose the patient was very sick, experienced fever, terrible headache, chills, intense body aches and joint pain. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events very sick, fever, terrible headache, chills, general body pain and joint pain was unknown at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: Very sick with first dose; Fever; Terrible headache; Chills; Intense body aches; Joint pain; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0190) via an unspecified route of administration in the left arm on 03Apr2021 at 16:30 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. The patient had no relevant medical history. The patient did not receive any other medicines within two weeks prior to the COVID-19 vaccine. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 04Apr2021, with first dose the patient was very sick, experienced fever, terrible headache, chills, intense body aches and joint pain. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events very sick, fever, terrible headache, chills, general body pain and joint pain was unknown at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Feeling hot, Inflammation, Skin swelling, Swelling of eyelid
Clinical narrative: Moderate swelling of eyelids and surrounding skin; Warmth/inflammation of cheeks and ears; Moderate swelling of surrounding skin; Warmth/inflammation of cheeks and ears; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: unknown) via an unspecified route of administration in the left arm on 05Apr2021 at 13:00 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. Medical history included autoimmune rash and had known allergies to sunscreen and cold temperature. Concomitant medications included dupilumab (DUPIXENT), loratadine (CLARITIN), plantago ovata (METAMUCIL) and fluticasone furoate (FLONASE SENSIMIST ALLERGY RELIEF); all from an unknown date for an unknown indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 02Apr2021 at 07:00, the patient experienced moderate swelling of eyelids and surrounding skin and warmth/inflammation of cheeks and ears. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported events. The clinical outcomes of moderate swelling of eyelids and surrounding skin and warmth/inflammation of cheeks and ears were recovering.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Dizziness, Fatigue, Headache, Pyrexia
Clinical narrative: Body chills; fever; headache; dizziness; exhausted; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old non-pregnant female patient received an unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in the right arm on 31Mar2021 at 13:45 (at the age of 55-year-old), as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications were not reported. The patient did not have any allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other medications within 2 weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 04Apr2021 at 16:00, the patient experienced body chills, fever, headache, dizziness and exhausted. The patient did not receive any treatment for the events. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event body chills, fever, headache, dizziness and exhausted was recovering.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Migraine, SARS-CoV-2 test
Clinical narrative: Daily headaches since vaccination; 4 migraines since vaccination.; This is a spontaneous report from a contactable nurse, the patient. A 38-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE: Lot Number: EP6955) via an unspecified route of administration in the left arm on 26Mar2021 at 14:30, (at the age of 38-years-old) as a single dose for COVID-19 immunisation. Medical history was reported as no. The patient did not receive any other medicines within two weeks prior to the COVID-19 vaccine. The patient previously received LAMICTAL for unknown indication on an unknown date and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On 30Mar2021, the patient underwent nasal swab (BinaxNOW Rapid Card) and the result was negative. On 06Apr2021, the patient underwent nasal swab and the result was pending. On 27Mar2021, the patient experienced daily headaches and 4 episodes of migraines since vaccination. Prior to vaccination, the patient had headache over a year ago and migraine over 18 months ago. The patient did not receive any treatment for the reported events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event headache and migraine was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Paraesthesia, Paraesthesia oral, Swollen tongue
Clinical narrative: Tongue tingling and swelling; Tongue tingling and swelling; Immediate headache; Tingling in arms/hands; This is a spontaneous report received from a contactable consumer (patient) via COVID-19 Adverse Event Self-Reporting Solution. A 35-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Er8730) via an unspecified route of administration in the arm right on 05Apr2021 at 10:00 (at the age of 35-years-old) as a single dose for COVID-19 immunization. The patient had no known allergies to medications, food or other products. Concomitant medications included sambucus nigra (ELDERBERRY), multivitamins, paracetamol (TYLENOL), birth control (unspecified); all from unknown dates for unknown indications. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient experienced immediate headache and tingling in arms/hands on 05Apr2021,at 10:00 and tongue tingling and swelling on 05Apr2021,at 10:30. Details were as follows: on 05Apr2021 at 10:00, the patient experienced immediate headache, within 2 minutes, tingling in arms/hands, which subsided and returned throughout the day, also within 30 minutes, the patient had tongue tingling and swelling. At 24h mark, tongue was still slightly tingly and slightly swollen but had subsided some. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of adverse events. The clinical outcomes of immediate headache, tingling in arms/hands and tongue tingling and swelling were recovering.  No follow-up attempts are needed. No further information is expected.
Age: 62.0
Sex: M
Vaccine: COVID19
Symptoms: Therapeutic response unexpected
Clinical narrative: vision began to be greatly enhanced; This is a spontaneous report from a contactable consumer, the patient. A 62-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730) via an unspecified route of administration in the arm left on 03Apr2021 at 13:00 (at the age of 62-year-old) as a single dose for COVID-19 immunisation. Medical history of the patient included penicillin allergy. Concomitant medications included atorvastatin calcium (LIPITOR) from unknown date, for unspecified indication. Prior to the vaccination, the patient was not diagnosed with COVID-19.  The patient did not receive any other vaccines within four weeks prior to the vaccination. Since the vaccination, the patient had not been tested for COVID-19. On 03Apr2021 at 13:30 the patient experienced that his vision began was greatly enhanced (altered visual depth perception).  He could see details like never before. Colors were brighter, more sharp and distinct. As best as the patient could describe it, he could see dimensionally, as in multi layers. On 06Apr2021, the patient did not even need reading glasses at all. His vision kept improving. The patient did not receive any treatment for the reported event.  The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event vision began to be greatly enhanced was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 52.0
Sex: M
Vaccine: COVID19
Symptoms: Herpes zoster
Clinical narrative: Shingles; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE;Lot Number: ER 8732) via an unspecified route of administration in the right arm on 30Mar2021 at 11:15 (at the age of 52-years-old), as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported.  Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 30Mar2021, the patient experienced shingles. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of shingles and included treatment with valacyclovir hcl. The clinical outcome of the event shingles was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.